Tandem Diabetes Care® Announces Expanded Pediatric Indication of t:slim® Insulin Pump for Ages 6 and Older

SAN DIEGO–(BUSINESS WIRE)–$TNDM #tandemdiabetes–Tandem Diabetes Care®, Inc. (NASDAQ: TNDM), a medical device company and
the manufacturer of the t:slim®, t:slim G4™ and t:flex® Insulin Pumps,
today announced FDA clearance of an expanded pediatric indication for
the t:slim® Insulin Pump, lowering its use to children age 6 and older
from children age 12 and older. The t:slim Pump is the first and only
touchscreen insulin pump cleared by the U.S. Food and Drug
Administration. This expanded pediatric indication applies to the
current t:slim Pump features, with no changes to the existing user
interface.

“The t:slim Pump has the look and feel of a modern consumer device,
which we believe makes it especially well-suited for school-aged
children who have grown up in a world of smartphones and tablets,” said
Kim Blickenstaff, president and Chief Executive Officer of Tandem
Diabetes Care. “This FDA clearance allows us to share this product with
a broader group of children with diabetes and their parents, who we
think can benefit greatly from our technology.”

The t:slim Pump consistently ranks #1 by pump users in independent
patient surveys1. The streamlined, user-friendly interface
provides rapid access to the features people use most, eliminating the
need for excessive scrolling and button pressing.

Some of the features of the t:slim Pump that stand out most to parents
and younger users include:

  • Small Size – The t:slim Pump is smaller than other durable
    pumps making it easy to wear, yet holds up to 300 units of insulin so
    it can keep up with a child’s changing insulin needs.
  • Durability – The t:slim Pump is made of aluminum, which is
    extremely durable and light, and the touchscreen is made of
    high-grade, shatter-resistant glass. The pump is also watertight, so
    you don’t have to worry about accidental dunks and splashes.2
  • Feature Lock – A feature lock can be used for young children
    not yet ready to operate the pump on their own. When activated, it can
    be used to prevent young users from being able to deliver a bolus or
    change any pump settings.
  • Insulin on Board (IOB) Calculations – The t:slim Pump tracks
    the amount of insulin that is still active in the body from previous
    boluses and uses this information to calculate future boluses. This
    helps prevent “stacking” insulin doses which can cause low blood sugar
    (hypoglycemia).
  • Personal Profiles – Up to six personal profiles can be created
    with unique names to cover a wide variety of situations, including
    school days, sleepovers, weekends or sport practice.
  • Missed Meal Bolus Reminder – This reminder can be set up to
    watch for boluses at specific times of day, and trigger a reminder if
    no bolus is delivered. This is especially helpful for children who may
    forget to bolus when they are away from home, such as during school
    lunch periods.
  • Site Reminder – This reminder is a programmable setting that
    reminds the user when it is time to change their infusion set. A
    specific time and date can be set for the reminder, which can be very
    useful for busy families on the go.

For more information about the t:slim Pump, or to find out about
insurance coverage options, please call 877-801-6901, Monday – Friday,
6am – 5pm Pacific Time.

About Tandem Diabetes Care, Inc.
Tandem Diabetes Care, Inc. (www.tandemdiabetes.com)
is a medical device company with an innovative, user-centric and
integrated approach to the design, development and commercialization of
products for people with diabetes who use insulin. The Company
manufactures and sells the t:slim® Insulin Pump, the slimmest and
smallest durable insulin pump currently on the market, the t:flex®
Insulin Pump, the first pump designed for people with greater insulin
requirements, and the t:slim G4™ Insulin Pump, the first CGM-enabled
pump with touch-screen simplicity. Tandem is based in San Diego,
California.

t:slim, t:flex, and Tandem Diabetes Care are registered trademarks, and
t:slim G4 is a trademark of Tandem Diabetes Care, Inc.

Follow Tandem Diabetes Care on Twitter @tandemdiabetes, use #tslim,
#tslimG4, #tflex, #tconnect, and $TNDM.
Follow Tandem Diabetes Care
on Facebook at www.facebook.com/TandemDiabetes.
Follow
Tandem Diabetes Care on LinkedIn at https://www.linkedin.com/company/TandemDiabetes.

Forward Looking Statement
This press release contains
“forward-looking statements” within the meaning of Section 27A of the
Securities Act of 1933, as amended, and Section 21E of the Securities
Exchange Act of 1934, as amended, that concern matters that involve
risks and uncertainties that could cause actual results to differ
materially from those anticipated or projected in the forward-looking
statements. These forward-looking statements relate to, among other
things, our belief that the t:slim Insulin Pump is well-suited for
school-aged children and that younger members of the diabetes community
and their parents can benefit from our technology. These statements are
subject to numerous risks and uncertainties, including the ability of
younger children and their parents to understand the features made
available by t:slim and the potential impact of those features on
diabetes treatment decisions, and their ability to operate t:slim in
accordance with applicable operating instructions, as well as other
risks identified in Tandem’s most recent Annual Report on Form 10-K and
Quarterly Report on Form 10-Q, and other documents that Tandem files
with the Securities and Exchange Commission. Investors are cautioned not
to place undue reliance on these forward-looking statements, which speak
only as of the date of this release. Tandem undertakes no obligation to
update or review any forward-looking statement in this press release
because of new information, future events or other factors.

1 dQ&A USA Connections Surveys 2013-2015.
2
IPX7 rating, tested to 3 feet of water for 30 minutes.

Contacts

Tandem Diabetes Care, Inc.
Media:
Steve Sabicer,
714-907-6264
ssabicer@thesabicergroup.com
or
Investor:
Susan
Morrison, 858-366-6900 x7005
smorrison@tandemdiabetes.com